接受联合抗逆转录病毒治疗的成人低水平HIV病毒血症与全因死亡率及严重非艾滋病事件:瑞典全国观察性研究结果
该瑞典全国观察性队列研究纳入1996—2017年启动cART的6956例HIV感染者,中位随访5.7年。与病毒学抑制(<50拷贝/mL)相比,低水平病毒血症(LLV,50—999拷贝/mL)与全因死亡率升高相关(aHR 2.2,95%CI 1.3—3.6);LLV 50—999拷贝/mL与AIDS或SNAEs风险增加无显著关联,但亚组分析中LLV 200—999拷贝/mL与SNAEs相关(aHR 2.0,95%CI 1.2—3.6)。
要点
- LLV(50—999拷贝/mL)与全因死亡率升高独立相关(aHR 2.2)。
- LLV 50—199拷贝/mL亦与死亡率升高相关(aHR 2.2)。
- LLV 200—999拷贝/mL亚组与SNAEs风险增加相关(aHR 2.0)。
核心结论
- 在接受cART的HIV成人中,低水平病毒血症与不良临床结局相关,尤其与全因死亡率升高相关。
研究设计与样本
- 瑞典全国观察性队列研究,基于InfCare HIV登记,纳入1996—2017年启动cART的6956例,中位随访5.7年。
主要发现
- 随访结束时60%为病毒学抑制(VS,<50拷贝/mL),9%为LLV(50—999拷贝/mL),31%为非抑制病毒血症(NSV,≥1000拷贝/mL)。
- 与VS相比,LLV与全因死亡率升高相关(aHR 2.2,95%CI 1.3—3.6)。
- LLV 50—999拷贝/mL与AIDS或SNAEs风险增加无显著关联,但亚组分析中LLV 200—999拷贝/mL与SNAEs相关(aHR 2.0,95%CI 1.2—3.6)。
临床怎么用
- 对cART期间LLV(50—999拷贝/mL)患者应加强临床监测与风险管理,尤其关注死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The impact of low levels of human immunodeficiency virus (HIV) RNA (low-level viremia [LLV]) during combination antiretroviral therapy (cART) on clinical outcomes is unclear. We explored the associations between LLV and all-cause mortality, AIDS, and serious non-AIDS events (SNAEs). METHODS: We grouped individuals starting cART 1996-2017 (identified from the Swedish InfCare HIV register) as virologic suppression (VS; <50 copies/mL), LLV (repeated viral load, 50-999 copies/mL), and nonsuppressed viremia (NSV; ≥1000 copies/mL). Separately, LLV was subdivided into 50-199 and 200-999 copies/mL (reflecting different definitions of virologic failure). Proportional-hazard models (including sex, age, pre-ART CD4 count and viral load, country of birth, injection drug use, treatment experience and interruptions, and an interaction term between viremia and time) were fitted for the study outcomes. RESULTS: A total of 6956 participants were followed for a median of 5.7 years. At the end of follow-up, 60% were categorized as VS, 9% as LLV, and 31% as NSV. Compared with VS, LLV was associated with increased mortality (adjusted hazard ratio [aHR], 2.2; 95% confidence interval [CI], 1.3-3.6). This association was also observed for LLV 50-199 copies/mL (aHR, 2.2; 95% CI, 1.3-3.8), but was not statistically significant for LLV 200-999 copies/mL (aHR, 2.1; 95% CI, .96-4.7). LLV 50-999 copies/mL was not linked to increased risk of AIDS or SNAEs, but in subanalysis, LLV 200-999 copies/mL was associated with SNAEs (aHR, 2.0; 95% CI, 1.2-3.6). CONCLUSIONS: In this population-based cohort, LLV during cART was associated with adverse clinical outcomes.
引用
- Elvstam O, Marrone G, Medstrand P, et al. All-Cause Mortality and Serious Non-AIDS Events in Adults With Low-level Human Immunodeficiency Virus Viremia During Combination Antiretroviral Therapy: Results From a Swedish Nationwide Observational Study. Clin Infect Dis. 2021. PMID: 32271361. doi:10.1093/cid/ciaa413
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。